Abstract
Graves' disease is an autoimmune disease and is the main cause of hyperthyroidism. This study aims to characterize the evolution of treatment with antithyroid drugs in patients with Graves' disease in a tertiary care referral center. We observed that the use of propylthiouracil was a predictor factor of a greater chance of having some adverse effect in relation to the use of methimazole. Regarding the evolution of treatment, high concentrations of TRAb were the main determinant for non-remission of the disease with the use of thionamides.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2019 Isabella Lucca de Campos Lima, Denise Engelbrecht Zantut Wittmann